Introduction {#S1}
============

The biological role of CRISPR has been identified as a prokaryotic adaptive immune system ([@B18]; [@B20]). Since then, the application of CRISPR has been expanding explosively in the field of biotechnology ([@B7]), especially because the components of CRISPR nucleases (i.e. crRNAs and Cas proteins) are separated functionally in the recognition of target nucleotide sequences and breakage of phosphodiester bonds in nucleic acids ([@B5]). Moreover, a specific protospacer adjacent motif (PAM) (∼3--5 bp) sequence must be located near the target sequence for the proper operation of the CRISPR/Cas system ([@B24]). In addition, the 5′-NGG sequence should be located right after target DNA sequences in the case of CRISPR/Cas9 ([@B19]).

The CRISPR/Cas9 nuclease has been widely used in gene knockout studies in eukaryotic cells by the highly specific digestion of target DNA sequences followed by *non*-homologous end joining, resulting in the insertion or deletion of target genes ([@B27]). In addition, site-specific genome editing can be achieved by the introduction of single-stranded oligonucleotides and/or double-stranded DNA fragments flanking homologous regions into prokaryotic or eukaryotic cells, respectively, which can be negatively selected by the CRISPR/Cas9 nuclease ([@B11]).

In addition to genome-editing tools, deactivated or dead Cas9 (dCas9) was created to be applied to artificial gene regulators ([@B12]). dCas9 has inactivated HNH and RuvC domains responsible for nuclease activity. It has been known that the target DNA sequence cannot be digested but is occupied by dCas9-crRNA complexes, which can affect the expression of target genes, and this is called CRISPR interference (CRISPRi) ([@B15]). When the dCas9-crRNA complex binds to the promoter of target genes, the initiation of transcription can be inhibited. If the complex binds to the coding region of the target gene, the elongation of transcription can be blocked ([@B21]). In prokaryotic cells, gene regulation is hardly achieved by RNA interference. Therefore, CRISPRi is very helpful in the engineering of microbial cells ([@B22]; [@B25]).

Since the bacterial adaptive immune system, CRISPR, has evolved to distinguish self and *non*-self target sequences ([@B16]), the presence of the PAM sequence near the target DNA is essential for the DNA double-strand breakage generated by the Cas9-crRNA complex ([@B1]). Such PAM dependence can narrow down the possible target sequences in the Cas9-crRNA complex. However, only binding to the target is necessary for the purpose of dCas9-crRNA, which suggests that PAM dependence is lower than Cas9-crRNA dependence.

In this study, we evaluated how strongly the dCas9-crRNA complex inhibits initiation and elongation in the transcription of the *gal* operon. Also, we tested whether dCas9-crRNA can recognize DNA targets with modified PAM sequences (NNG and NGN). Our results demonstrate that cellular metabolic rates can be controlled with CRISPRi and that a loose PAM sequence dependence can expand the DNA targets of dCas9-crRNA.

Materials and Methods {#S2}
=====================

Strains and Culture Conditions {#S2.SS1}
------------------------------

*Escherichia coli* K-12 DH5α and MG1655 strains were used as a cloning host and a dCas9 expression host, respectively ([Table 1](#T1){ref-type="table"}). *E. coli* cells were grown routinely in LB medium. When needed, antibiotics such as ampicillin (50 μg/ml), kanamycin (25 μg/ml), and spectinomycin (75 μg/ml) were used.

###### 

Strains and plasmids used in this study.

  Name          Characteristics                                                                             Source/reference
  ------------- ------------------------------------------------------------------------------------------- ------------------
  **Strain**                                                                                                
  DH5α          *fhuA2 lac*Δ*U169 phoA glnV44* Φ*80*′ *lacZ*Δ*M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17*    Laboratory stock
  MG1655        F^--^ *ilvG rfb*-50 *rph*-1                                                                 S. Adhya
  HK1060        MG1655, Δ*araBAD*:*P*~*BAD*~-*dcas9*-KmR                                                    This study
  **Plasmid**                                                                                               
  pKD46         pSC101*ori* ^ts^, *araC*, λ *red* genes, AmpR                                               [@B6]
  pdCas9        P15A *ori*, *dcas9* gene, CmR                                                               Addgene \#46569
  pTargetF      pBR322 *ori*, crRNA scaffold, SpR                                                           Addgene \#62226
  pHK459        PAM(TGG), pBR322 *ori*, crRNA target ^498^AGGCTGTAACTGCGGGATCA^517^ in *galK*), SpR         This study
  pBJ003        PAM(CGG), pBR322 *ori*, crRNA target ^573^CGAACAGAAATCACCAATGC^592^ in *galT*), SpR         This study
  pBJ004        PAM(TGG), pBR322 *ori*, crRNA target ^406^TACGTTGAAAGCTTCCCGAC^425^ in *galE*), SpR         This study
  pBJ005        PAM(TGG), pBR322 *ori*, crRNA target ^--30^TTCGCATCTTTGTTATGCTA^--11^ in P*~gal~*), SpR     This study
  pBJ021        PAM(CAG), pBR322 *ori*, crRNA target ^503^GTAACTGCGGGATCATGGAT^522^ in *galK*), SpR         This study
  pBJ022        PAM(GCG), pBR322 *ori*, crRNA target ^489^CCAGTTTGTAGGCTGTAACT^508^ in *galK*), SpR         This study
  pBJ023        PAM(ATG), pBR322 *ori*, crRNA target ^497^TAGGCTGTAACTGCGGGATC^516^ in *galK*), SpR         This study
  pBJ024        PAM(GGA), pBR322 *ori*, crRNA target ^499^GGCTGTAACTGCGGGATCAT^518^ in *galK*), SpR         This study
  pBJ025        PAM(AGC), pBR322 *ori*, crRNA target ^504^TAACTGCGGGATCATGGATC^523^ in *galK*), SpR         This study
  pBJ026        PAM(TGT), pBR322 *ori*, crRNA target ^482^CAGAAAACCAGTTTGTAGGC^501^ in *galK*), SpR         This study
  pBJ027        PAM(AAG), pBR322 *ori*, crRNA target ^--1^GAAATAACCATAGCATAACA^--20^ in P*~gal~*), SpR      This study
  pBJ028        PAM(GCG), pBR322 *ori*, crRNA target ^--6^AACCATAGCATAACAAAGAT^--25^ in P*~gal~*~)~, SpR    This study
  pBJ029        PAM(ATG), pBR322 *ori*, crRNA target ^--31^TTTCGCATCTTTGTTATGCT^--12^ in P*~gal~*~)~, SpR   This study
  pBJ030        PAM(AGA), pBR322 *ori*, crRNA target ^--2^AAATAACCATAGCATAACAA^--21^ in P*~gal~*), SpR      This study
  pBJ031        PAM(TGC), pBR322 *ori*, crRNA target ^--5^TAACCATAGCATAACAAAGA^--24^ in P*~gal~*), SpR      This study
  pBJ032        PAM(GGT), pBR322 *ori*, crRNA target ^--29^TCGCATCTTTGTTATGCTAT^--10^ in P*~gal~*), SpR     This study

Genomic Integration {#S2.SS2}
-------------------

The primers used in this study are listed in [Table 2](#T2){ref-type="table"}. In order to make a *dcas9*-KmR cassette, the *dcas9* gene was amplified using plasmid pdCas9 \[a gift from Luciano Marraffini, Addgene plasmid \#46569 ([@B2])\] as a template and fused with a kanamycin resistance gene by overlap PCR. The PCR products of the *dcas9*-KmR cassette with a homologous region for recombineering at the *araBAD* promoter in the chromosome were electroporated into *E. coli* K-12 MG1655 cells harboring plasmid pKD46 ([@B6]) to generate *E. coli* HK1060 (Δ*araBAD*:*P*~*BAD*~-*dcas9*-KmR). Then, plasmid pKD46 was cured at 42°C. The disruption of the *araBAD* genes and the integration of the *dcas9* gene in HK1060 cells were confirmed by PCR.

###### 

Primers used in this study.

  Name               Sequence (5′→3′)                                  Description
  ------------------ ------------------------------------------------- ----------------------------------------
  Cas-AraC-F1        GCTTTTTATCGCAACTCTCTACTGTTTCTCCATACCCGTTTTTTTGG   Construction of *cas9*-KmR cassette
                     ATGGAGTGAAACGATGGATAAGAAATACTCAATAGGCT            
  KmR-AraD-R4        GTGGTGCCGGTTGCTGGAATCGACTGACCCGCCTGCGCCCAGATGGT   Construction of *cas9*-KmR cassette
                     GGCGTGGCGCGAGTGTAGGCTGGAGCTGCTTCGAAGTT            
  Cas-KmR-OR2        GACGGATCCCCGGAATTCAGTCACCTCCTAGCTGACTCAAA         Construction of *cas9*-KmR cassette
  Cas-KmR-OF3        GCTAGGAGGTGACTGAATTCCGGGGATCCGTCGACCTGCAG         Construction of *cas9*-KmR cassette
  Ara_F1             AGCAGCTCCGAATAGCGCCCTTCCCCTTGC                    Confirmation of Δ*araBAD*
  AraD_500dn         CCAGCCAGAAGGAGACTTCTGTCCCTTG                      Confirmation of Δ*araBAD*
  Sm_ATG_R           GATACTGGGCCGGCAGGCGCTCCATTGCCC                    Construction of crRNA plasmids
  Sm_TAA_F           GCAATGGAGCGCCTGCCGGCCCAGTATCAG                    Construction of crRNA plasmids
  pTarget_seq        AACGCCTGGTATCTTTATAGTCCTGTCG                      Sequencing of crRNA plasmids
  Cas-galK-WF        AGGCTGTAACTGCGGGATCAGTTTTAGAGCTAGAAATAGCAAG       Construction of pHK459 plasmid
  Cas-galK-WR        TGATCCCGCAGTTACAGCCTACTAGTATTATACCTAGGACTG        Construction of pHK459 plasmid
  *galT*\_Target_F   CGAACAGAAATCACCAATGCGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ003 plasmid
  *galT*\_Target_R   GCATTGGTGATTTCTGTTCGACTAGTATTATACCTAGGACTG        Construction of pBJ003 plasmid
  *galE* Target_F    TACGTTGAAAGCTTCCCGACGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ004 plasmid
  *galE*\_Target_R   GTCGGGAAGCTTTCAACGTAACTAGTATTATACCTAGGACTG        Construction of pBJ004 plasmid
  P*gal* Target_F    TTCGCATCTTTGTTATGCTAGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ005 plasmid
  P*gal* Target_R    TAGCATAACAAAGATGCGAAACTAGTATTATACCTAGGACTG        Construction of pBJ005 plasmid
  *galK*\_CAG_F      GTAACTGCGGGATCATGGATGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ021 plasmid
  *galK*\_CAG_R      ATCCATGATCCCGCAGTTACACTAGTATTATACCTAGGACTG        Construction of pBJ021 plasmid
  *galK*\_GCG_F      CCAGTTTGTAGGCTGTAACTGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ022 plasmid
  *galK*\_GCG_R      AGTTACAGCCTACAAACTGGACTAGTATTATACCTAGGACTG        Construction of pBJ022 plasmid
  *galK*\_ATG_F      TAGGCTGTAACTGCGGGATCGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ023 plasmid
  *galK*\_ATG_R      GATCCCGCAGTTACAGCCTAACTAGTATTATACCTAGGACTG        Construction of pBJ023 plasmid
  *galK*\_GGA_F      GGCTGTAACTGCGGGATCATGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ024 plasmid
  *galK*\_GGA_R      ATGATCCCGCAGTTACAGCCACTAGTATTATACCTAGGACTG        Construction of pBJ024 plasmid
  *galK*\_AGC_F      TAACTGCGGGATCATGGATCGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ025 plasmid
  *galK*\_AGC_R      GATCCATGATCCCGCAGTTAACTAGTATTATACCTAGGACTG        Construction of pBJ025 plasmid
  *galK*\_TGT_F      CAGAAAACCAGTTTGTAGGCGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ026 plasmid
  *galK*\_TGT_R      GCCTACAAACTGGTTTTCTGACTAGTATTATACCTAGGACTG        Construction of pBJ026 plasmid
  P*gal*\_AAG_F      GAAATAACCATAGCATAACAGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ027 plasmid
  P*gal*\_AAG_R      TGTTATGCTATGGTTATTTCACTAGTATTATACCTAGGACTG        Construction of pBJ027 plasmid
  P*gal*\_GCG_F      AACCATAGCATAACAAAGATGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ028 plasmid
  P*gal*\_GCG_R      ATCTTTGTTATGCTATGGTTACTAGTATTATACCTAGGACTG        Construction of pBJ028 plasmid
  P*gal*\_ATG_F      TTTCGCATCTTTGTTATGCTGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ029 plasmid
  P*gal*\_ATG_R      AGCATAACAAAGATGCGAAAACTAGTATTATACCTAGGACTG        Construction of pBJ029 plasmid
  P*gal*\_AGA_F      AAATAACCATAGCATAACAAGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ030 plasmid
  P*gal*\_AGA_R      TTGTTATGCTATGGTTATTTACTAGTATTATACCTAGGACTG        Construction of pBJ030 plasmid
  P*gal*\_TGC_F      TAACCATAGCATAACAAAGAGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ031 plasmid
  P*gal*\_TGC_R      TCTTTGTTATGCTATGGTTAACTAGTATTATACCTAGGACTG        Construction of pBJ031 plasmid
  P*gal*\_GGT_F      TCGCATCTTTGTTATGCTATGTTTTAGAGCTAGAAATAGCAAG       Construction of pBJ032 plasmid
  P*gal*\_GGT_R      ATAGCATAACAAAGATGCGAACTAGTATTATACCTAGGACTG        Construction of pBJ032 plasmid
  *galE*-RTL         CCACCGTTTATGGCGATCAG                              RT-qPCR for transcripts of *galE* gene
  *galE*-RTR         GTTCCACCATCAGCTTGCTT                              RT-qPCR for transcripts of *galE* gene
  *galK*-RTL         GCCTCTATGCGCGATGATTT                              RT-qPCR for transcripts of *galK* gene
  *galK*-RTR         CACCTTTGTCGCCAATCACA                              RT-qPCR for transcripts of *galK* gene
  16S-RTL            CAGCAGCCGCGGTAATAC                                RT-qPCR for 16S rRNA
  16S-RTR            ACCAGGGTATCTAATCCTGT                              RT-qPCR for 16S rRNA

Plasmid Construction {#S2.SS3}
--------------------

To generate the crRNA expression plasmids, pTargetF (a gift from Sheng Yang, Addgene plasmid \#62226) was used as a template to amplify 0.9 and 1.2-kb fragments with primer pairs of Cas-galK-WF and Sm_ATG_R and Sm_TAA_F and Cas-galK-WR, respectively. These two fragments were purified for isothermal assembly using Gibson Assembly^®^ Master Mix (NEB, MA, United States) to make pHK459 plasmid ([Table 1](#T1){ref-type="table"}). Other crRNA plasmids carrying the spectinomycin resistance gene as a selection marker were constructed by Gibson Assembly in the same manner. Target sequences recognized by crRNAs were designed in the DNA sequences (i.e. the *gal* promoter and the *galE*, *galT*, and *galK* genes) in the *gal* operon. The extended −10 region was selected as the DNA target in the *gal* promoter. For the experiments with modified PAM sequences, we constructed additional crRNA plasmids targeting the *gal* promoter and the *galK* gene. All the crRNA plasmids were confirmed by Sanger sequencing and transformed into HK1060 cells for the growth assay.

Growth Assay {#S2.SS4}
------------

HK1060 cells carrying each crRNA plasmid were grown in LB broth containing spectinomycin at 37°C overnight as starter cultures. Next, 1.0% of cells were inoculated in 25 ml of M9 minimal medium containing sodium succinate (final 20 mM) as a carbon source and spectinomycin in 250-ml flasks. crRNAs were expressed constitutively, and gratuitous [L]{.smallcaps}-arabinose (final 1 mM) was added for the expression of dCas9 proteins to form the dCas9-crRNA complex in HK1060 cells carrying crRNA plasmids. To determine whether the transcription of the *gal* operon could be negatively regulated by the dCas9-crRNA complex, [D]{.smallcaps}-galactose (final 20 mM) was added as an additional carbon source 6 h after the beginning of flask cultures. Optical density at 600 nm was measured every 3 h to monitor cellular growth using an Ultrospec 8000 spectrophotometer (GE Healthcare, Uppsala, Sweden).

Transcript Analysis {#S2.SS5}
-------------------

Expression levels of *galE* and *galK* genes were monitored using RT-qPCR. HK1060 cells carrying each crRNA plasmid were grown M9 minimal medium containing sodium succinate (final 20 mM) as a carbon source with or without [L]{.smallcaps}-arabinose (final 1 mM). [D]{.smallcaps}-galactose (final 20 mM) was added 6 h after the beginning of flask cultures. RNAs were isolated using the RNeasy^®^ Mini kit (Cat. No. 74104; Qiagen, Hilden, Germany) 3 h after the addition of [D]{.smallcaps}-galactose. PCR primer sequences for the target genes were designed at the Universal Probe Library Assay Design Center^[1](#footnote1){ref-type="fn"}^ and listed in [Table 2](#T2){ref-type="table"}. Quantitative real-time PCR (RT-qPCR) reactions were carried out on a LightCycler 96 (Roche Diagnostics, Mannheim, Germany) using the RealHelix^TM^ qPCR kit (Nanohelix, South Korea). Five nanograms of each total RNA were used in RT-qPCR reactions under the following conditions: cDNA synthesis (50°C, 40 min); denaturation (95°C, 12 min); amplification for 50 cycles (95°C, 20 s; 60°C, 1 min). The raw fluorescence data were normalized against the expression level of 16S ribosomal RNA. In order to calculate the relative abundance of *galE* (374--453 base region from +1 start codon) and *galK* (895--963 base region) transcripts, mRNA levels of *galE* and *galK* genes in the presence of [L]{.smallcaps}-arabinose were divided by mRNA levels of the corresponding genes in the absence of [L]{.smallcaps}-arabinose.

Metabolite Analysis {#S2.SS6}
-------------------

The concentrations of [D]{.smallcaps}-galactose in the culture medium were determined by high-performance liquid chromatography (HPLC, RID-10A RI monitor, Shimadzu, Japan) with an Aminex HPX-87H column (300 × 7.8 mm, Hercules, BioRad), as described previously ([@B9]). After centrifugation of the cell culture broth, the supernatant was filtered through a 0.2-μm syringe filter. The column was isocratically eluted at 47°C with a flow rate of 0.5 ml min^--1^ using 0.01 N H~2~SO~4~.

Results {#S3}
=======

Repression of *gal* Operon by CRISPRi {#S3.SS1}
-------------------------------------

Cellular growth and [D]{.smallcaps}-galactose utilization were monitored to assess how well CRISPRi interferes with transcription of the *gal* operon. Since CRISPRi can inhibit the initiation and elongation of transcription, the *gal* promoter and the *gal* structural genes (*galE*, *galT*, and *galK*) were used as the DNA targets of the dCas9-crRNA complex ([Figure 1A](#F1){ref-type="fig"}). Cells carrying the [L]{.smallcaps}-arabinose-inducible *dcas9* gene were transformed with various crRNA plasmids. The transformed cells were grown in succinate minimal media in the presence or absence of [L]{.smallcaps}-arabinose, which can serve as a gratuitous inducer. Succinate was used as a carbon source to prevent carbon catabolite repression. At the early exponential phase (∼OD~600~ of 0.3), [D]{.smallcaps}-galactose was added to the cell culture at 6 h after inoculation. If the *gal* transcription was not inhibited by dCas9-crRNAs, the increase of cellular growth and the consumption of [D]{.smallcaps}-galactose could be observed.

![Regulation of *gal* operon and control of [D]{.smallcaps}-galactose metabolic rates by CRISPRi. **(A)** Expression of *gal* promoter and structural genes regulated by dCas9-crRNAs. The control of the *gal* promoter and structural *galETK* genes was used as a model system for comparing the transcriptional initiation and elongation by CRISPRi. The target DNAs in the *gal* operon can be attached by active dCas9-crRNA complexes, which are formed by dCas9 proteins expressed in the presence of *non*-metabolizable [L]{.smallcaps}-arabinose, and crRNAs transcribed constitutively in cells. [D]{.smallcaps}-galactose metabolism depends on the expression of [D]{.smallcaps}-galactose metabolic enzymes in the *gal* operon. **(B)** Growth profiles of HK1060 cells carrying specific crRNAs targeting *gal* promoter and structural *galETK* genes. Retarded cell growth was observed due to the repression of galactose enzymes by [L]{.smallcaps}-arabinose. **(C)** Change of residual [D]{.smallcaps}-galactose concentration in culture media. [D]{.smallcaps}-galactose was added at 6 h and monitored until the late stationary growth phase. **(D)** [D]{.smallcaps}-galactose consumption rates affected by CRISPRi. The concentration changes of residual [D]{.smallcaps}-galactose between 9 and 12 h were used for the calculation of [D]{.smallcaps}-galactose consumption rates. Arrows indicate when [L]{.smallcaps}-arabinose (if needed) and [D]{.smallcaps}-galactose were added. NC, not consumed.](fmicb-11-00282-g001){#F1}

HK1060 cells were transformed with crRNA plasmids expressing crRNAs recognizing the DNA targets with the original PAM sequence (5′-NGG). As a result, in the absence of [L]{.smallcaps}-arabinose, all the transformant cells reached an OD~600~ of 4, and consumed [D]{.smallcaps}-galactose (total 20 mM) within 18 h ([Figures 1B,C](#F1){ref-type="fig"}). However, cell growth rates were decreased in the presence of *non*-metabolizable [L]{.smallcaps}-arabinose. This means [L]{.smallcaps}-arabinose-induced dCas9 can combine with crRNA to make dCas9-crRNA, which can interfere with the transcription of [D]{.smallcaps}-galactose metabolic genes.

In the case of the *gal* promoter, [D]{.smallcaps}-galactose was not consumed at all until the end of the experiment ([Figure 1C](#F1){ref-type="fig"}). The *gal* promoter is composed of two overlapped extended −10 promoters ([@B14]), which may be covered thoroughly by dCas9-crRNA complex. These results indicate that transcriptional initiation can be completely inhibited by CRISPRi.

In the case of structural genes as the inhibition targets, the cell growth and [D]{.smallcaps}-galactose consumption were differentially retarded. This means that the expression of *gal* genes was repressed partially by the blocking of transcriptional elongation. In the profiles of HPLC, the level of gratuitous [L]{.smallcaps}-arabinose was not changed in any of the samples, because the *ara* operon was disrupted by the integration of the *dcas9* gene in HK1060 cells. It was confirmed that our model CRISPRi system operated fully and partially in the promoter and structural genes of [D]{.smallcaps}-galactose metabolism, respectively.

Repression of *gal* Promoter by CRISPRi With Expanded PAM Sequences {#S3.SS2}
-------------------------------------------------------------------

In order to determine whether CRISPRi follows the PAM sequence rule (5′-NGG) of CRISPR/Cas9, various crRNA plasmids were designed, as shown in [Table 1](#T1){ref-type="table"}. Modified PAM sequences (5′-NGN and 5′-NNG) were tested in the *gal* promoter as the DNA target of the dCas9-crRNA complex ([Figures 2A,B](#F2){ref-type="fig"}).

![Tight repression of the *gal* promoter by CRISPRi with modified PAM sequences. **(A)** The inability of the RNA polymerase to recognize and attach to the *gal* promoter region, which is occupied by the dCas9-crRNA complex, inhibits the initiation of transcription. Blue and red boxes indicate overlapped --10 regions of *P*~1~ and *P*~2~ promoters, respectively. The *gal* promoter-specific crRNA was transcribed from plasmid pBJ005. **(B)** Design of target DNA sequences with modified PAM sequences in *gal* promoter. The *gal P*~1~ and *P*~2~ promoters overlapped each other. The modified PAM sequences of NNG (top) and NGN (bottom) were evaluated by growth profiles **(C)**, utilization of [D]{.smallcaps}-galactose **(D)**, and comparison of [D]{.smallcaps}-galactose consumption rates **(E)**. [D]{.smallcaps}-galactose was added at 6 h, and the concentration changes of residual [D]{.smallcaps}-galactose between 9 and 12 h were used to calculate [D]{.smallcaps}-galactose consumption rates. NC, not consumed. Arrows indicate when [L]{.smallcaps}-arabinose (if needed) and [D]{.smallcaps}-galactose were added, and when samples were taken for RNA extraction.](fmicb-11-00282-g002){#F2}

In addition to in NGG (TGG), the growth retardation was observed in the case of NAG (AAG), NTG (ATG), and NGA (AGA) ([Figure 2C](#F2){ref-type="fig"}). Moreover, [D]{.smallcaps}-galactose consumption was not observed with the expanded PAM sequences until the end of the experiments ([Figure 2D](#F2){ref-type="fig"}). The [D]{.smallcaps}-galactose consumption rates (between 9 and 12 h in graphs) in the cases of NCG (GCG), NGC (TGC), and NGT (GGT) were not changed in the presence (dCas9 expressed) or absence (dCas9 not expressed) of [L]{.smallcaps}-arabinose ([Figure 2E](#F2){ref-type="fig"}). Transcript analysis showed that the differential repression of the *gal* promoter by dCas9-crRNA complexes with the modified PAM sequences. The order of repression was as follows: NGG (TGG) \> NAG (AAG) \> NGA (AGA) \> NTG (ATG) ([Figure 3A](#F3){ref-type="fig"}). In the cases of NCG (GCG), NGC (TGC), and NGT (GGT), the repression of *gal* promoter could not be observed in the RT-qPCR experiment. These data showed that even weakly attached dCas9-crRNA complex with modified PAM sequences did not result in sufficient *gal* transcription for galactose metabolism.

![Relative transcript analysis of *galE* **(A)** and *galK* **(B)** genes affected by the presence of dCas9-crRNA complexes. *galE* and *galK* transcripts were analyzed for monitoring of transcriptional initiation and elongation, respectively. The relative abundance of *galE* and *galK* transcripts was obtained by calculating the normalized transcript data of *galE* and *galK* genes in the presence of [L]{.smallcaps}-arabinose (*dcas9* induced) divided by those in the absence of [L]{.smallcaps}-arabinose (*dcas9* uninduced).](fmicb-11-00282-g003){#F3}

Exploration of *galK* Structural Gene as the Target of CRISPRi With Expanded PAM Sequences {#S3.SS3}
------------------------------------------------------------------------------------------

The same set of modified PAM sequences (5′-NGN and 5′-NNG) was tested in the *galK* structural gene as the DNA target of the dCas9-crRNA complex ([Figures 4A,B](#F4){ref-type="fig"}). As a result, cell growth was affected slightly in the cases of NGG (TGG), NTG (ATG), and NGA (GGA) as PAM sequences ([Figure 4C](#F4){ref-type="fig"}). According to the [D]{.smallcaps}-galactose consumption rate, the order of interference was as follows: NGG (TGG) \> NGA (GGA) \> NTG (ATG) ([Figures 4D,E](#F4){ref-type="fig"}). The [D]{.smallcaps}-galactose consumption rate (between 9 and 12 h in graphs) in the case of ATG was decreased from ∼3 mM/h (dCas9 not expressed due to the absence of [L]{.smallcaps}-arabinose) to ∼1 mM/h (dCas9 expressed by [L]{.smallcaps}-arabinose).

![Differential repression of *galK* structural gene by dCas9-crRNAs recognizing modified PAM sequences. **(A)** Precise target recognition and proper PAM sequences are required for the blocking of transcriptional elongation in the *galK* gene by CRISPRi. The *galK*-specific crRNA was transcribed from plasmid pHK459. **(B)** Design of target DNA sequences with modified PAM sequences in *galK* gene. The modified PAM sequences of NNG (top) and NGN (bottom) were evaluated by growth profiles **(C)**, utilization of [D]{.smallcaps}-galactose **(D)**, and comparison of [D]{.smallcaps}-galactose consumption rates **(E)**. [D]{.smallcaps}-galactose was added at 6 h, and the concentration changes of residual [D]{.smallcaps}-galactose between 9 and 12 h were used to calculate [D]{.smallcaps}-galactose consumption rates. Arrows indicate when [L]{.smallcaps}-arabinose (if needed) and [D]{.smallcaps}-galactose were added, and when samples were taken for RNA extraction.](fmicb-11-00282-g004){#F4}

We analyzed the abundance of mRNA of the *galK* gene in the presence or absence of dCas9-crRNA complexes ([Figure 3B](#F3){ref-type="fig"}). The *galK* transcripts in downstream region of dCas9-crRNA complex-binding sites were monitored by RT-qPCR. In case of NGG (TGG) as a PAM sequence, the transcriptional elongation of the *galK* gene was affected by CRISPRi. However, any significant interference in the transcriptional elongation was not clearly observed in other PAM sequences using RT-qPCR analysis.

Discussion {#S4}
==========

CRISPR interference can regulate the expression of DNA targets by inhibiting the transcription process. Designed target recognition sequences of modular crRNAs can be used to bind any DNA target to dCas9-crRNA complexes ([@B8]). While nonsense point mutation can affect cells permanently by deleting the function of the target gene, dCas9-mediated gene expression control allows the selection of desired time points ([@B23]). Endogenous competing pathway genes can be repressed by CRISPRi in *E. coli* for metabolic engineering ([@B10]). Even if the genes are essential for growth, metabolic engineering with CRISPRi provides the necessary metabolites without disturbing cell growth ([@B4]).

Gene regulation using CRISPRi is carried out in two ways. First, binding of the dCas9-crRNA complex in the promoter region can fully repress transcriptional initiation. Also, elongation of transcription can be blocked by positioning the dCas9-crRNA complex in the middle of the open reading frame of the target gene ([@B3]). In our study, the *gal* operon and galactose metabolism were used as a model to demonstrate how dCas9-crRNA can precisely regulate the expression of target genes (*gal* promoter and structural *galE*, *galT*, and *galK* genes) and the corresponding metabolism ([Figure 1A](#F1){ref-type="fig"}).

Non-metabolizable [L]{.smallcaps}-arabinose-induced dCas9 proteins can combine with target-specific crRNAs to make the dCas9-crRNA complex, which can bind to the DNA targets in the galactose promoter, preventing cellular consumption of [D]{.smallcaps}-galactose ([Figure 1D](#F1){ref-type="fig"}). When the *gal* structural genes (*galE*, *galT*, and *galK*) were designed as the DNA targets of the dCas9-crRNA complex, we observed differential [D]{.smallcaps}-galactose consumption rates. RT-qPCR analysis showed that the initiation of *galE* transcription was significantly repressed, and the elongation of *galK* transcription was slightly blocked the dCas9-crRNAs with TGG as PAM sequence ([Figure 3](#F3){ref-type="fig"}). These results might be explained by that RNA polymerase cannot bind to the *gal* promoter occupied by the dCas9-crRNA complex, but RNA polymerase can pass through some of the roadblocks of dCas9-crRNA during transcriptional elongation. Although all enzymes encoded by *galE*, *galT*, and *galK* genes are essential in galactose metabolism, the most retarded cell growth was observed in *galE-*targeted cells ([Figure 1B](#F1){ref-type="fig"}), presumably because *galE* mutant cells cannot grow well due to the depletion of pyrimidine nucleotides ([@B13]).

The PAM sequence should be considered in CRISPR technologies when the target DNA sequence is designed. The biological role of the PAM sequence is to discriminate between *non*-self DNA from outside cells and self DNA stored in the chromosome in bacterial adaptive immune system. It has been known that the PAM sequence is indispensable for DNA cleavage by the Cas9-crRNA complex ([@B17]). It has been reported that the hydrogen bonds between nucleotides in the PAM sequence (5′-NGG) and the two arginine residues (Arg1333 and Arg1335) in the Cas9 protein are important in DNA cleavage ([@B1]). The PAM dependence in the CRISPR/Cas9 system has been studied for expanding the target sequence and reducing off-target activity. Reportedly, the 5′-NGA sequence can function as PAM, although the modified PAM sequence exhibits less *gfp* gene cleavage activity ([@B26]). It is still unclear whether the PAM sequence is essential in the recognition of target sequences in CRISPR/dCas9 in bacterial cells.

The PAM dependence in CRISPRi was investigated using regulation of the *gal* promoter ([Figure 2](#F2){ref-type="fig"}) and the *galK* gene ([Figure 4](#F4){ref-type="fig"}) by dCas9-crRNA complex. The differential repressions of *gal* promoter by modified PAM sequences were observed by RT-qPCR analysis ([Figure 3A](#F3){ref-type="fig"}). The order of *gal* promoter repression showed that target binding affinities of dCas9-crRNAs with modified PAM sequences might be weaker than those with the original PAM sequence (NGG). However, the CRISPRi-induced growth retardation and totally impaired [D]{.smallcaps}-galactose consumption suggest that NAG, NTG, and NGA can function as the original PAM sequence (NGG) in the *gal* transcription initiation ([Figure 2](#F2){ref-type="fig"}). This means that the *gal* promoter even weakly occupied by dCas9-crRNA complex cannot be properly recognized by the RNA polymerase in the cells.

In the case of the *galK* structural gene as the DNA target of CRISPRi, transcriptional elongation can be clearly modulated by CRISPRi with the original PAM sequence (NGG) based on the results of cellular growth, metabolic rates, and transcript abundance. Since the original PAM sequence occurs frequently in the open reading frame of common genes, the expression of essential genes can be attenuated by CRISPRi with the original PAM sequence.

These results showed that the DNA target sequence for CRISPRi can be expanded, allowing the design of more specific target sequences such as narrow promoter regions. Our results also show that cellular growth and metabolic rates can be controlled by dCas9-crRNAs. The information about CRISPRi with expanded PAM sequences may be useful in the design of DNA targets and crRNAs for fine gene regulation in microbial biotechnology.
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